YLIU-5-162-1|CAS 2417685-83-5|DC Chemicals

Cas No.:	2417685-83-5
Chemical Name:	YLIU-5-162-1
SMILES:	O=C(NC1=CC(C(F)(F)F)=CC(CN2CCN(CC)CC2)=C1)C3=CC=C(C)C(C4=NN5C(C=C4)=NC(NC(C6CC6)=O)=C5)=C3
Formula:	C₃₂H₃₄F₃N₇O₂
M.Wt:	605.67

Cat. No.	Product name	Field of application
DC73569	Lepzacitinib (ATI-1777)	Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases.
DC72210	NDI-034858(Zasocitinib)	NDI034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM.
DC72043	VVD-118313	VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer.
DC70831	TD-1473	TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2.TD-1473 inhibited cytokine-induced phosphorylation of STAT1 in mouse primary colonic epithelial cells with pIC50 values for inhibition against IL-6, IFNα and IFNγ were 7.3, 6.8 and 7.0.TD-1473 demonstrated JAK inhibitory activity in ex vivo mouse colon and human IBD patient colonic tissue. TD-1473 (Izencitinib) is under development for the treatment of ulcerative colitis.
DC70233	Londamocitinib（AZD4604）	AZD4604 (AZD-4604) is a potent, selective Janus-associated kinase 1 (JAK1) inhibitor with anti-inflammatory effect.
DC47591	JAK-IN-14	JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).
DC47132	JAK1-IN-8	JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1.
DC47066	Ifidancitinib	Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.
DC47038	Fosifidancitinib	Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.
DC47030	Ilunocitinib	Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).